We are pleased to announce the release of Vitrolife Group’s Annual Report for 2025. Despite a volatile market, we delivered a resilient performance, continued to gain market share in key regions, and maintained our strategic focus on growth, innovation, and operational excellence.
Annual Report
Vitrolife Group Annual and Sustainability Report for 2025
Latest financial report
Fourth quarter & full year report 2025
We achieved strong sales growth in local currencies for the final quarter of the year, despite significant macroeconomic headwinds. Sales for the fourth quarter increased by 6% in local currencies excluding discontinued business.
Vitrolife Group acquires eFertility
An innovative system and software company transforming IVF clinic management with cutting edge solutions
We are delighted to announce that the Vitrolife Group successfully completed the acquisition of eFertility (STB Zorg B.V.). This acquisition is a key element of the Vitrolife Group’s strategy to bring increased standardisation and digitalisation to IVF clinics around the world.
“The acquisition of eFertility represents a significant step in the Vitrolife Group’s strategy to transform and digitalise the IVF patient journey. By incorporating eFertility’s technologies into our platform, we are making critical advancements towards the development of a seamlessly integrated and more efficient clinic workflow." said Bronwyn Brophy O´Connor, CEO of Vitrolife Group.
Capital Markets Day 2023
The Vitrolife Group hosted a Capital Markets Day where we shared details of our future vision for reproductive health, our strategic plan for the company and the role we want to play in bringing more innovation to market and helping increase capacity and access for patients.
If you missed it, you can log in and see the recording under resources.
Excellence in reproductive health
By combining Igenomix’s reproductive genetic testing services with Vitrolife’s IVF medical devices, we are now better than ever positioned to serve our customers and their patients, so that more families can fulfil the dream of having a healthy baby.
Reasons to invest in Vitrolife Group
- Underlying resilient market growth.
- High quality brands linked with outstanding service and support.
- Proven track record of profitable growth.
- Innovation and technology leader within fertility.
- Ambitious strategy and long-term objectives.
Financial Calendar
-
23 Apr 2026
Interim report Q1, 2026
-
05 May 2026
Annual General Meeting 2026
-
16 Jul 2026
Interim report Q2, 2026
The Nasdaq OMX Sweden Small Cap 30 ESG Responsible™ Index
Vitrolife Group included in the new Nasdaq OMX Sweden Small Cap 30 ESG Responsible Index™
IR Contact
Jenny Jakobson
Welcome to contact us if you have questions about the Vitrolife Group in relation to investments and the listing on Nasdaq Stockholm.
Financial Reports
Read Vitrolife Group's financial reports, including the latest release of the annual and sustainability report and interim reports.
Sustainability
Ensuring sustainability in everything we do is one of our key strategic priorities. Learn more on our approach and sustainability themes.
Corporate governance
Vitrolife AB is a publicly traded Swedish company listed on NASDAQ Stockholm. The company's corporate governance policies comply with Swedish laws and regulations.